Dean Rudge
Senior Reporter
Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent-infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
Inflexion Outlines Rosemont Investment And Eyes More Generics Deals
In an exclusive interview with Generics Bulletin, Inflexion’s Ben Long reveals his ambitions for newly-acquired UK-based liquids generics specialist Rosemont Pharmaceuticals, including to drive investment in R&D and expand the company’s international footprint.
Mylan Symbicort Trial Looms As Company Eyes First US Generic
A trial will begin next month in Mylan’s bid to overcome patents shielding AstraZeneca’s Symbicort respiratory brand in the US. With rival Teva having previously settled ANDA action, Mylan is in the driving seat for a first substitutable generic.
Bankruptcy Court Gives Green Light To Akorn Sale
Just three years after Fresenius Kabi agreed a $4.75bn takeover of the US injectables specialist, Akorn has obtained approval from a US bankruptcy court for its sale to the company’s existing lenders, having filed for Chapter 11 bankruptcy earlier this year.
Neuraxpharm Snapped Up By Private Equity In Europe’s Largest Deal
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.
Alvogen’s Lotus Picks Up Darbepoetin Alfa Rights In Asia
Lotus Pharmaceuticals has expanded its biosimilar pipeline to five by bringing in rights in Taiwan and South East Asia markets to Chong Kun Dang Pharmaceutical’s biosimilar of Kyowa Kirin’s Nesp (darbepoetin alfa).
Reddy’s Settles On $7bn Revlimid But Natco Maintains The Lead
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.